Mid-Volga scientists bet on well-aimed strikes on cancers
8 Dec '16
Researchers at the Lobachevsky University (UNN) in Nizhny Novgorod, in Russia’s mid-Volga area, are developing multifunctional nanodimensional therapeutic agents based on protein toxins and beta emitters for combinatory cancer treatment, the UNN website announced.
The project developers are reportedly shooting for a maximum possible targeted effect and selectivity in the agent’s impact on malignant tumor cells, looking into its therapeutic properties on modeled human tumors. They used the yttrium isotope that helped pass on to the nanoparticles some beta emitter properties very useful in radionuclide therapy. To make sure the nanoagent produces combinatory effect on a tumor a recombinant protein toxin was included in the agent, which inhibits protein synthesis in cells.
The UNN developers believe nanoparticles provide the best platform known today for the creation of biocompatible multifunctional compounds with high efficacy, because the particles offer what the scientists claim is a unique set of properties, including the programmability of certain physical and chemical characteristics and the availability of chemically active functional clusters on their surface which enable easy modification of particles to suit specific therapeutic tasks.
The project is being pushed by a UNN-based team led by Andrei Zvyagin, a senior research fellow at UNN’s Institute of Biology and Biomedicine and professor at Australia’s Macquarie University.